TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY

NARecruitingINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

November 11, 2020

Primary Completion Date

September 1, 2025

Study Completion Date

September 1, 2030

Conditions
Carcinoma, Squamous CellOesophageal Cancer
Interventions
RADIATION

External beam radiotherapy

External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy

DRUG

Bintrafusp alfa

Bintrafusp alfa will be given i.v. every three weeks on day 1, 22, and 43 at a dose of 2400 mg.

DRUG

Paclitaxel

Paclitaxel 50 mg/m2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36.

DRUG

Carboplatin

Carboplatin AUC = 2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36.

Trial Locations (1)

1100 DD

RECRUITING

Academic Medical Center, Medical Oncology, Amsterdam

All Listed Sponsors
collaborator

UMC Utrecht

OTHER

collaborator

Catharina Ziekenhuis Eindhoven

OTHER

collaborator

Institute Verbeeten

OTHER

collaborator

Elisabeth-TweeSteden Ziekenhuis

OTHER

collaborator

Leiden University Medical Center

OTHER

collaborator

Radiotherapeutic Institute Friesland

OTHER

collaborator

Frisius Medisch Centrum

OTHER

collaborator

Radiotherapy Group Deventer

OTHER

collaborator

Deventer Ziekenhuis

OTHER

collaborator

Rijnstate Hospital

OTHER

collaborator

Erasmus Medical Center

OTHER

collaborator

The Netherlands Cancer Institute

OTHER

collaborator

Isala

OTHER

collaborator

University Medical Center Groningen

OTHER

collaborator

Ziekenhuisgroep Twente

OTHER

lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

NCT04481256 - TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY | Biotech Hunter | Biotech Hunter